What Is Compounded Semaglutide? Safety & Legality

*This article is for education only and does not constitute medical advice. It does not recommend or evaluate any specific pharmacy, provider, or product, and it is not a guide to sourcing medication. Decisions about GLP-1 therapy belong with a licensed prescriber who knows your history.*

---

The ad shows up in every feed eventually: "Semaglutide for a fraction of the price. No insurance needed. Free shipping." Telehealth ads targeting DFW patients — and everyone else — have spent the past two years making cheaper "semaglutide" feel like a normal consumer purchase.

Most people who click it never learn what they are actually buying. This guide explains what compounded semaglutide is, how it differs from Wegovy and Ozempic, why it existed in the first place, what changed when the shortage ended, and what the FDA's safety alerts actually say. The goal is to make you a better question-asker — not to tell you what to do.

What Is Compounded Semaglutide?

Compounded semaglutide is a pharmacy-made preparation of semaglutide — the same active molecule in Wegovy and Ozempic — assembled from purchased active pharmaceutical ingredient (API) rather than supplied by Novo Nordisk. The compounding pharmacy sources the API, combines it with sterile diluents, fills vials or syringes, and dispenses it under a prescription.

It is not a generic. A generic drug replicates an FDA-approved product and has its own abbreviated approval pathway proving sameness. A compounded preparation has neither. The specific vial you receive has not been through FDA pre-market review for strength, purity, sterility, and stability — the pharmacy is responsible for those, under a different (and lighter) regulatory framework than brand-name manufacturing.

That is the definitional core: same molecule, different regulatory pathway, different assurance level. Whether that trade-off is acceptable for a given patient is a clinical conversation — but you cannot have that conversation without knowing the trade-off exists.

What Compounding Is — and When It Is Permitted

Pharmacy compounding is a legitimate, decades-old practice grounded in a real principle: some patients need medications that are not commercially available in the right form, dose, or formulation (an allergy-free version, a liquid for someone who cannot swallow tablets). Federal law recognizes two compounding channels under the Food, Drug, and Cosmetic Act:

✦503A pharmacies compound for an *individual patient* with a valid prescription. They are regulated primarily by state boards of pharmacy and follow USP standards for sterile preparation (USP <797>) and hazardous drug handling (USP <800>).
✦503B outsourcing facilities can compound *larger batches* without patient-specific prescriptions. They face heavier federal requirements — current good manufacturing practice (cGMP) and direct FDA inspection — though still less pre-market scrutiny than an approved drug application.

What compounding was never intended to be is a mass-market alternative to an available branded drug. That line held until 2023, when demand for GLP-1s broke the supply chain.

Why Compounded Semaglutide Existed: The Shortage Era

When the FDA declared semaglutide injections in shortage beginning in 2022, a legal window opened: federal law permits compounding of a shortage drug under specific exemptions, and through 2022 and 2023, 503B facilities scaled up semaglutide production to fill the gap. Telehealth platforms built entire business models on that window — cheap, accessible, prescription-only-ish "semaglutide" with glossy apps and monthly subscriptions. Tirzepatide and liraglutide followed the same pattern during their own shortage windows.

Then the shortages ended. The FDA determined the semaglutide injection shortage resolved in early 2026 (tirzepatide followed later in the year), and in August 2026 the agency clarified how compounding policy applies once a shortage is declared resolved: the exemption that permitted mass compounding narrows back to the standard framework, where compounding a commercially available drug requires meeting specific conditions — and bulk 503B compounding of semaglutide loses its footing entirely. The agency has also formally proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list, which would close the bulk-compounding route for these molecules as the proposal is finalized.

The practical translation: the regulatory justification for widely available, low-cost compounded GLP-1s has been removed. Some 503A patient-specific compounding continues where a prescriber documents a genuine clinical need for a customized preparation — but the era of pharmacy-scale compounded semaglutide as a mainstream consumer product is ending. If you currently use a compounded GLP-1, that is exactly the conversation to be having with your prescriber now, before anything changes with your supply — not after.

What the FDA Safety Alerts Actually Say

In July and August 2026, the FDA issued safety alerts to health care providers and compounders about dosing errors with compounded injectable semaglutide. It is worth being precise about what these alerts do and do not say.

What they say: the FDA has received reports of patients receiving incorrect doses of compounded injectable semaglutide. The errors trace to concentration and labeling confusion — compounded products prepared at variable concentrations, with dosing expressed in different units (mg, mL, "pen clicks," insulin-style units), which invites conversion mistakes during measurement and administration. The consequences reported include overdoses (severe gastrointestinal effects, hypoglycemia) and underdoses (treatment failure — a patient believes they are on a therapeutic dose and is not). The alerts instruct compounders to standardize labeling and concentration expression, and providers to verify concentration and dose units before administering or dispensing.

What they do not say: that every compounded preparation is dangerous, or that compounding pharmacies are inherently reckless. These alerts target a specific failure mode — unit and concentration confusion in pharmacy-prepared injectables — not the entire compounding profession. Many 503A and 503B pharmacies follow rigorous sterile procedures and test their preparations.

But the alerts land on top of a second, quieter safety layer: independent analyses of compounded semaglutide products have documented variability in potency, sterility, and pH between sources. The dosing-error alerts are the visible tip; product variability is the structural issue beneath them. Together they explain why "same molecule" does not automatically mean "same medicine."

A note on salt forms, because ads exploit the confusion: some compounded products historically used semaglutide salts (such as semaglutide sodium) rather than the base form used in FDA-approved products. The FDA has stated that salt forms are not the same as the FDA-approved active ingredient. If a product's labeling does not make its form plain, that is a question for your prescriber and pharmacist — not a reason to guess.

Questions to Ask Your Prescriber or Pharmacy

If you are currently using — or considering — a pharmacy-prepared GLP-1, these are the questions a careful clinician expects to hear:

1. "Is the preparation semaglutide base or a salt form?" FDA-approved products use semaglutide base; the agency considers salt forms different active ingredients.

2. "What concentration is the vial, and what units is the dose expressed in?" This is the exact failure point the FDA alerts flag. Ask until you can state it back: "My dose is X mg, drawn as Y units from a vial labeled Z mg/mL."

3. "Who compounded it — a 503A pharmacy or a 503B outsourcing facility?" The two channels carry different regulatory obligations; your clinician should know which one your prescription came from.

4. "Is there a certificate of analysis, and does the pharmacy test for potency and sterility?" Reputable compounders can produce documentation; inability to is a red flag.

5. "Given the policy changes, what is my transition plan?" The compounding window is narrowing. A good clinician has an answer before you need one.

That last question deserves urgency. Patients who started on compounded semaglutide during the shortage now face a transition decision — to a branded product, or to documented patient-specific compounding if clinically warranted. For patients weighing branded alternatives, our head-to-head guide on switching from semaglutide to tirzepatide covers the evidence for that specific move; our GLP-1 coverage and cash-pay guide covers the access and cost side. And if you have a procedure coming up, timing questions around GLP-1 therapy are covered separately in our perioperative safety guide.

Sources

1. FDA dosing-error safety alerts: U.S. Food and Drug Administration drug safety communications to health care providers and compounders regarding dosing errors with compounded injectable semaglutide, July 20, 2026 and August 1, 2026. The alerts describe reported overdoses and underdoses tied to concentration and labeling confusion between dosing units, and direct compounders to standardize labeling.

2. Compounding policy as shortages ease: FDA clarification of compounding policies applying once national GLP-1 shortages are declared resolved, August 2026 — narrowing the enforcement-discretion window that had permitted large-scale GLP-1 compounding since 2023.

3. 503B bulks-list proposal: FDA proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list (proposed July 2026), removing the legal basis for bulk compounding of these molecules.

4. Shortage resolution: FDA Drug Shortages Database — semaglutide injection shortage resolution (early 2026); tirzepatide resolution followed later in 2026.

5. Prior LuxeFit regulatory coverage: Compounded GLP-1 vs Brand-Name comparison documents the compounding-landscape context and product-variability findings cited above.

*Regulatory status summarized as of August 2026. This article does not recommend any specific product, pharmacy, or provider.*

---

*LuxeFit Wellness provides physician-supervised evaluation for patients navigating GLP-1 therapy decisions. If you have questions about your current regimen or transition options, schedule a consultation with our clinical team.*

Frequently Asked Questions

What is compounded semaglutide?

Compounded semaglutide is a pharmacy-prepared version of semaglutide — the active ingredient in Wegovy and Ozempic — made from purchased active pharmaceutical ingredient rather than supplied by the brand manufacturer. It contains the same molecule but has not been through FDA pre-market review as a finished product; the compounding pharmacy is responsible for potency, sterility, and labeling under state and federal compounding rules.

Is compounded semaglutide the same as Wegovy or Ozempic?

Same molecule, different product. Wegovy and Ozempic are FDA-approved drugs manufactured under cGMP with lot-release testing and clinical-trial evidence behind the exact product. Compounded semaglutide shares the active molecule but relies on the compounding pharmacy's own quality processes, and the specific preparation has not been studied in trials. Some compounded products have also used semaglutide salts, which the FDA does not consider the same as the approved active ingredient.

Is compounded semaglutide safe?

"Safe" is not a yes-or-no answer here. The FDA's 2026 alerts document dosing errors tied to concentration and labeling confusion — overdoses causing severe GI effects and hypoglycemia, and underdoses causing treatment failure. Independent analyses have found potency and sterility variability between sources. None of that means every compounded preparation is hazardous, and none of it means every compounder is careless — but it does mean the assurance level is materially lower than an FDA-approved product, and the dosing-unit confusion is a specific, documented risk you can screen for by asking questions.

Is compounded semaglutide still available now that the shortage is over?

Availability is narrowing. The FDA resolved the semaglutide injection shortage in early 2026 and has since clarified that the compounding exemptions tied to the shortage narrow with it; a formal proposal would remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Patient-specific 503A compounding may continue where clinical need is documented, but mass-market compounded semaglutide is winding down. If you rely on it, talk to your prescriber about a transition plan now.

Why is compounded semaglutide cheaper?

Because it does not carry the costs behind the brand price: a decade of clinical trials, cGMP manufacturing, lot-release testing, pharmacovigilance, and the rest of the approval infrastructure. The molecule is the cheap part. The lower price reflects a lighter regulatory and quality-assurance footprint — which can be acceptable in specific clinical circumstances with a prescriber's judgment, and which is precisely what the FDA's narrowing policy is re-weighing now that branded supply is stable.

What should I ask my provider about compounded semaglutide?

Start with five: base form or salt? What concentration and units, stated plainly? 503A or 503B? Is there a certificate of analysis with potency and sterility testing? And — given the policy changes — what is my transition plan? A clinician who cannot or will not answer these is telling you something.

Ready to Start Your Protocol?

Schedule a virtual consultation with a licensed physician to determine if peptide therapy is right for you.

Start Your Consultation

This article is for educational purposes only and does not constitute medical advice. Information on this website should not be used to diagnose, treat, or prevent any medical condition. Consult with a licensed physician before starting any new therapy.

What Is Compounded Semaglutide? Safety, Legality, and What Patients Should Know